Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

The hallmarks of a CHB cure are:

  • Elimination of HBsAg - the surface antigen of the hepatitis B virus, and
  • HBsAg seroconversion - which occurs when a specific antibody becomes detectable in the blood and the corresponding antigen becomes undetectable, in this case HBsAg

In the study, decrease of HBsAg and HBsAg seroconversion was achieved in 30% of TG1050-injected mice.

Earlier studies have proven that TG1050 is able to induce a robust, multi-specific and long-lasting immune response against the hepatitis B virus. These latest results, which show that TG1050 is able to decrease HBsAg and lead to anti-HBsAg seroconversion in HBV persistent mouse models, support the move to a first-in-man study and the start of clinical development.


Explore further

Risk of hepatitis D higher among HIV infected and injection drug users

Provided by European Association for the Study of the Liver
Citation: Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure (2015, April 23) retrieved 22 October 2019 from https://medicalxpress.com/news/2015-04-immunotherapeutic-tg1050-early-potential-chronic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more